# Future Gen Biopharm

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/future-gen-biopharm

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.futuregen.com.cn
- Total disclosed funding: $62M
- Latest round: Series B (Mar 12, 2021)
- Investors on record: 5

## About

Founded in 2014 and based in Beijing, China, Future Gen Biopharm is a medical company that focuses on the development of antibody drugs and reagent antibodies that can be used in scientific research and clinical applications based on biotechnology. Zhaoyu Jin, the chairman and CEO of the Company, holds a PhD degree in Pharmacology from the University of Pennsylvania in the United States, used to work for Genentech and other biopharmaceutical companies. The company's manufacturing base was completed in Beijing in 2020. It received clinical approval for its M108 program in 2021. In March 2021, Future Gen Biopharm raised series B funding.

Future Gen Biopharm's main product category is innovative biopharmaceuticals for tumor immunotherapy. It designs and develop innovative monoclonal antibody, bis-antibody, poly-antibody and ADC drugs based on its STEP platform, biofunctional analysis platform, and CMC production platform. Products within include FG-B901, FG-B310, FG-M234. The company's products have been used in oncology and immune diseases.

## Funding rounds

- Series B, Mar 12, 2021, $46M — Lilly Asia Ventures, China International Capital Corporation, MSA Capital, Shanghai Jianyi Private Equity Fund Management, DYEE Capital
- Series A, Apr 16, 2018, $16M — Lilly Asia Ventures

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- MSA Capital (https://capitalatlas.ai/funds/msa-capital) — Series B
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series B
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series B